Ionis Pharmaceuticals price target lowered to $62 from $65 at Piper Sandler
Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $62 from $65 and keeps an ...
Positive Outlook for Crinetics Pharmaceuticals: Strategic Advancements and Strong Financial Position Drive Target Price Increase
Citi analyst David Lebowitz has maintained their bullish stance on CRNX stock, giving a Buy rating yesterday. David Lebowitz’s rating is ...
Business Wire22h
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the ...